In the BioTherapeutics master’s specialisation you focus on the development of novel therapeutic approaches to treat immune-based disorders by applying systems immunological and metabolism methods and advanced drug delivery technology.
What does this master’s programme entail?
The BioTherapeutics master’s specialisation focusses on research-oriented education into the development of state-of-the-art therapies using novel biologics, such as vaccines, therapeutic proteins and peptides, and gene therapy products for inflammatory diseases, including atherosclerosis and skin disease. Integration of experimental in-vitro and in-vivo data is aimed to aid a smoother and speedier transition from preclinical research to pharmacological interventions, and the delivery of drugs in the human body.
Read more about the BioTherapeutics programme.
Why study BioTherapeutics at Leiden University?
- The master's specialisation BioTherapeutics is by the interdisciplinary research division of the Leiden Academic Centre for Drug Research (LACDR) bearing the same name BioTherapeutics. The division focuses on a wide variety of research themes from vaccination and other immunotherapeutical and metabolic strategies for the treatment of atherosclerosis to the formulation of biopharmaceuticals and innovative research into skin barrier function and drug delivert via the skin.
- The strength of the programme is the research-oriented approach and the tailored programme designed for each student individually.
- You study in an internationally, top-ranked research institute.
Find more reasons to choose BioTherapeutics at Leiden University.
BioTherapeutics: the right master’s programme for you?
If you are interested in research training in specific drug delivery techniques, and the development of new therapeutic approaches to treat immune-based disorders, such as atherosclerosis, metabolic disorders and inflammatory skin diseases, this master’s programme is the right choice.
Read more about the entry requirements for BioTherapeutics.